The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Provides broad overview of Company's research and early development programs expected to continue to fuel future growth Highlights ... · ACCESS Newswire · Moderna, Inc. The above button links to ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

Moderna (MRNA) is in the early stages of developing a hantavirus vaccine, though its availability could be years away. Shares are up ~14% in Friday afternoon trading. Hantavirus has received renewed ...

Moderna Inc. said it’s researching vaccines to protect against hantaviruses, even as public health experts downplay the risk the deadly pathogen aboard a cruise ship could become a significant threat.

April 24 (Reuters) - German biotech company CureVac sued Moderna (MRNA.O), opens new tab in Delaware federal court on Friday, alleging that Moderna's COVID-19 vaccine Spikevax infringed CureVac ...

Moderna’s mRNA-based combination vaccine against both flu and COVID-19 has gotten the green light in Europe—but it continues to be shelved in the US, where it was developed. This week, the European ...

A critically acclaimed musical about Barack Obama is coming to Washington DC for the first time, with tickets still available for its limited run. After making its world premiere in Los Angeles in ...

As mentioned, Moderna experienced significant growth in the early stages of the coronavirus crisis as it quickly commercialized and delivered a vaccine. This was the company's first and only product ...

Moderna CEO Stéphane Bancel’s total compensation remained remarkably stable last year at $19.9 million, even as the vaccines company navigated a “challenging regulatory and business environment.” ...

Moderna, Inc. settles its LNP patent dispute with Arbutus and Genevant for a $950 million upfront payment, eliminating a major litigation overhang. MRNA secures royalty-free access to critical LNP ...